Sulbactam and Durlobactam Combination as a Newer Antibiotic for Carbapenem-Resistant Acinetobacter baumannii Infections

This review explores the evolution of the concept of Healthcare-Associated Pneumonia (HCAP) in light of the 2016 guidelines from the Infectious Diseases Society of America (IDSA). These updated guidelines prioritize patient-specific risk factors over healthcare system interactions in pneumonia classification. Recent research has revealed that the risk of contracting Multidrug-Resistant (MDR) pathogens is more closely linked to individual patient risk factors than to healthcare system interactions. Consequently, administering empiric antibiotic therapy targeting MDR bacteria for patients meeting HCAP criteria is discouraged unless specific risk factors for MDR infections are identifiable. Hospital-Acquired Pneumonia (HAP) is a significant challenge, particularly in intensive care units, leading to elevated hospitalization costs and extended inpatient care. The review also delves into the emergence and global prevalence of Carbapenem-Resistant Acinetobacter baumannii (CRAB) infections, known for their high mortality rates. In response to the rising threat of CRAB infections, the review introduces Sulbactam-Durlobactam (SUL-DUR) as a promising therapeutic solution. It examines the unique characteristics of Sulbactam and Durlobactam, both individually and in combination, and their potential in treating CRAB infections. Clinical trial data is presented to demonstrate the effectiveness and safety of SUL-DUR in addressing Hospital-Acquired Bacterial Pneumonia (HABP), Ventilator-Associated Bacterial Pneumonia (VABP), and bacteremia caused by the Acinetobacter baumannii-Calcoaceticus complex. The review also covers FDA-approved prescribing guidelines, dosage recommendations, adverse reactions, drug interactions, and usage in specific populations, including pregnant and lactating individuals. The management of renal and hepatic impairment and underscores the importance of monitoring for potential overdosage. While initial clinical evidence is promising, further research is essential to establish the full efficacy and safety profile of SUL-DUR.